In another work from Leone et al., the cotreatment with Vorinostat, a histone deacetylase inhibitor (HDACI) and either of two different EGFR-TKIs (Gefitinib, Erlotinib), was shown to suppress the c-MYC-regulated NRF2 function, increasing the levels of KEAP1 and promoting oxidative stress-dependent apoptosis in NSCLC cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.